Angelman Syndrome Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

An Open-Label Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of OV101 in Individuals With Angelman Syndrome
Condition: Angelman Syndrome Intervention: Drug: OV101 Sponsor: Ovid Therapeutics Inc. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 20, 2019 Category: Research Source Type: clinical trials

Ovid Therapeutics Announces Plans to Move into a Phase 3 Trial in Pediatric Patients Based on End-of-Phase 2 Meeting for OV101 in Angelman Syndrome
NEW YORK, Dec. 06, 2018 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced plans to move ahead... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - December 6, 2018 Category: Pharmaceuticals Source Type: clinical trials

Angelman & Rett Syndrome: Interaction and Communication
Conditions: Behavior, Child; Parent-Child Relations; Communication Interventions: Behavioral: Observation; Behavioral: Parental experiences Sponsors: Universitaire Ziekenhuizen Leuven; KU Leuven Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 25, 2018 Category: Research Source Type: clinical trials